GUARDANT HEALTH, INC. vs RadNet, Inc., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where GH and RDNT diverge most: on operating margin, GH reads -38.5% and RDNT reads 6.3%; on return on invested capital, GH reads -29.0% and RDNT reads 1.9%. The rest of the comparable metrics sit closer together. What RDNT's price implies is a somewhat stretched bet versus history (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | GH | RDNT |
|---|---|---|
| Price | $157.44 | $75.49 |
| Market cap | $20.9B | $5.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/B | — | 4.26 |
| P/S | 17.68 | 2.62 |
| EV/EBITDA | — | 27.2 |
| Revenue growth | +42.6% | +18.8% |
| Operating margin | -38.5% | 6.3% |
| Net margin | -38.3% | -0.9% |
| Return on equity | — | -1.5% |
| Return on assets | -23.7% | -0.5% |
| Return on invested capital | -29.0% | 1.9% |
| FCF yield | -1.1% | 5.2% |
| Debt / equity | — | 0.98 |
| Current ratio | 4.03 | 1.48 |
| Altman Z (solvency) | 4.56 | 1.88 |
| Piotroski F (quality) | 3 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.